Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
| ▸ | NAT1 | P18440 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7159338 | 0.83 | — | — | |
| SCHEMBL13656879 | 0.82 | GABBR2 (0.44) | SMN1; SMN2ALDH1A1GABBR2GABBR1 | |
| SCHEMBL7155129 | 0.82 | GABBR2 (0.44) | SMN1; SMN2ALDH1A1GABBR2GABBR1 | |
| SCHEMBL7159675 | 0.81 | GABBR2 (0.34) | GABBR2GABBR1 | |
| SCHEMBL7158271 | 0.78 | CA1 (0.44) | ALDH1A1CA2POLB | |
| SCHEMBL7158822 | 0.73 | MAOA (0.38) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL7636123 | 0.71 | GAA (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL8327560 | 0.69 | ALDH1A1 (0.34) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL13468674 | 0.68 | PTGS1 (0.38) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL6306524 | 0.68 | GABBR2 (0.44) | SMN1; SMN2ALDH1A1GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6533825-B2 | For colouring/pigmenting high-molecular-weight organic material | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-03-18 | — | — | US | disclosed |
| US-20020095046-A1 | Dibenzonaphthyrones | NESVADBA PETER (CH) | 2002-07-18 | — | — | US | disclosed |
| EP-1015518-B1 | ISOXINDIGOS USEFUL AS COLORANTS AND PREPARATION THEREOF | CIBA SC HOLDING AG (CH) | 2002-05-15 | — | — | EP | disclosed |
| US-6323267-B1 | MIXING HIGH MOLECULAR WEIGHT ORGANIC OR INORGANIC MATERIAL WITH ISOXINDIGO COMPOUND | CIBA SPECIALTY CHEMICALS CORP. | 2001-11-27 | — | — | US | disclosed |
| US-6281361-B1 | COLORING, PIGMENTING | CIBA SPECIALTY CHEMICALS CORP. | 2001-08-28 | — | — | US | disclosed |
| EP-1095041-A2 | DIBENZONAPHTHYRONES AND THEIR USE FOR COLOURING/PIGMENTING HIGH-MOLECULAR-WEIGHT ORGANIC MATERIAL | Ciba SC Holding AG (CH) | 2001-05-02 | — | — | EP | disclosed |
| EP-1015518-A1 | ISOXINDIGOS USEFUL AS COLORANTS AND PREPARATION THEREOF | Ciba SC Holding AG (CH) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999052909-A2 | DIBENZONAPHTHYRONES AND THEIR USE FOR COLOURING/PIGMENTING HIGH-MOLECULAR-WEIGHT ORGANIC MATERIAL | CIBA SPECIALTY CHEMICAL HOLDING INC. (CH) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999013007-A1 | ISOXINDIGOS USEFUL AS COLORANTS AND PREPARATION THEREOF | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095046-A1 | Dibenzonaphthyrones | CYP1B1, CYP7B1, CYP1A1 | SMN1; SMN2 3980/4885ALDH1A1 127/4885CA2 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.